ATIC and triple-negative breast carcinoma: Small molecule inhibitors, LSN3213128 and 326203-A, which target 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), a subunit of the ATIC enzyme, are being evaluated for treatment of triple-negative breast cancer [41].